Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
As of close of business last night, Exact Sciences Corp’s stock clocked out at $45.70, up 1.74% from its previous closing price of $44.92. In other words, the price has increased by $1.74 from its previous closing price. On the day, 1.53 million shares were traded. EXAS stock price reached its highest trading level at $46.43 during the session, while it also had its lowest trading level at $44.63.
Ratios:
To gain a deeper understanding of EXAS’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 8.18 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 113.87. For the most recent quarter (mrq), Quick Ratio is recorded 1.92 and its Current Ratio is at 2.15. In the meantime, Its Debt-to-Equity ratio is 1.16 whereas as Long-Term Debt/Eq ratio is at 1.04.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, RBC Capital Mkts on March 13, 2025, initiated with a Sector Perform rating and assigned the stock a target price of $52.
On January 23, 2025, Barclays started tracking the stock assigning a Overweight rating and target price of $70.
On August 28, 2024, Wells Fargo started tracking the stock assigning a Overweight rating and target price of $75.Wells Fargo initiated its Overweight rating on August 28, 2024, with a $75 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Nov 13 ’24 when Conroy Kevin T bought 19,500 shares for $51.35 per share. The transaction valued at 1,001,325 led to the insider holds 1,074,191 shares of the business.
Baranick Brian sold 929 shares of EXAS for $65,030 on Oct 08 ’24. The EVP, GM, Precision Oncology now owns 12,758 shares after completing the transaction at $70.00 per share. On Oct 08 ’24, another insider, Baranick Brian, who serves as the Officer of the company, bought 929 shares for $70.00 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, EXAS now has a Market Capitalization of 8489004032 and an Enterprise Value of 10226754560. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.08 while its Price-to-Book (P/B) ratio in mrq is 3.53. Its current Enterprise Value per Revenue stands at 3.707 whereas that against EBITDA is 343.629.
Stock Price History:
The Beta on a monthly basis for EXAS is 1.12, which has changed by -0.2629032 over the last 52 weeks, in comparison to a change of 0.08275449 over the same period for the S&P500. Over the past 52 weeks, EXAS has reached a high of $79.62, while it has fallen to a 52-week low of $40.62. The 50-Day Moving Average of the stock is -10.91%, while the 200-Day Moving Average is calculated to be -17.94%.
Shares Statistics:
It appears that EXAS traded 2.19M shares on average per day over the past three months and 2067070 shares per day over the past ten days. A total of 185.62M shares are outstanding, with a floating share count of 182.94M. Insiders hold about 1.51% of the company’s shares, while institutions hold 99.52% stake in the company. Shares short for EXAS as of 1740700800 were 10663382 with a Short Ratio of 4.87, compared to 1738281600 on 9930985. Therefore, it implies a Short% of Shares Outstanding of 10663382 and a Short% of Float of 5.8000002.
